Paul Hastings Advised NervGen Pharma on its Bought Deal Offering
Paul Hastings LLP advised NervGen Pharma Corp. in connection with the company’s bought deal offering. NervGen Pharma Corp. (TSXV: NGEN) is a clinical stage biotech company dedicated to developing innovative treatments that enable the nervous system to repair itself following damage, whether due to injury or disease.
Partner and co-chair of Equity Capital Markets and co-chair of the Corporate Life Sciences Group Seo Salimi led the Paul Hastings team.
More details on the transaction can be found here.
With widely recognized elite teams across 18 core practices, Paul Hastings is a premier law firm with a culture of excellence focused on providing intellectual capital and superior execution globally to the world's leading investment banks, asset managers and corporations.